YiChang HEC ChangJiang Pharmaceutical Co Ltd
HKEX:1558
Intrinsic Value
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. engages in the development, manufacturing and selling of pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases... [ Read More ]
The intrinsic value of one YiChang HEC ChangJiang Pharmaceutical Co Ltd stock under the Base Case scenario is 22.64 HKD. Compared to the current market price of 12.5 HKD, YiChang HEC ChangJiang Pharmaceutical Co Ltd is Undervalued by 45%.
Valuation Backtest
YiChang HEC ChangJiang Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling YiChang HEC ChangJiang Pharmaceutical Co Ltd stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
YiChang HEC ChangJiang Pharmaceutical Co Ltd
| Current Assets | 6.6B |
| Cash & Short-Term Investments | 3.8B |
| Receivables | 1.1B |
| Other Current Assets | 1.7B |
| Non-Current Assets | 6.8B |
| Long-Term Investments | 12.3m |
| PP&E | 3.8B |
| Intangibles | 2.9B |
| Other Non-Current Assets | 120.1m |
| Current Liabilities | 5.7B |
| Accounts Payable | 185.4m |
| Accrued Liabilities | 1.2B |
| Short-Term Debt | 2B |
| Other Current Liabilities | 2.3B |
| Non-Current Liabilities | 872m |
| Long-Term Debt | 507.1m |
| Other Non-Current Liabilities | 364.9m |
Earnings Waterfall
YiChang HEC ChangJiang Pharmaceutical Co Ltd
|
Revenue
|
6.3B
CNY
|
|
Cost of Revenue
|
-1.3B
CNY
|
|
Gross Profit
|
5B
CNY
|
|
Operating Expenses
|
-2.1B
CNY
|
|
Operating Income
|
2.9B
CNY
|
|
Other Expenses
|
-905.4m
CNY
|
|
Net Income
|
2B
CNY
|
Free Cash Flow Analysis
YiChang HEC ChangJiang Pharmaceutical Co Ltd
Profitability Score
Profitability Due Diligence
YiChang HEC ChangJiang Pharmaceutical Co Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Score
YiChang HEC ChangJiang Pharmaceutical Co Ltd's profitability score is 55/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
YiChang HEC ChangJiang Pharmaceutical Co Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Score
YiChang HEC ChangJiang Pharmaceutical Co Ltd's solvency score is 71/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
YiChang HEC ChangJiang Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for YiChang HEC ChangJiang Pharmaceutical Co Ltd is 13.46 HKD with a low forecast of 13.33 HKD and a high forecast of 13.86 HKD.
Shareholder Return
Price
YiChang HEC ChangJiang Pharmaceutical Co Ltd
| Average Annual Return | -16.4% |
| Standard Deviation of Annual Returns | 35.58% |
| Max Drawdown | -86% |
| Market Capitalization | 11B HKD |
| Shares Outstanding | 879 967 700 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
YiChang HEC ChangJiang Pharmaceutical Co. Ltd. engages in the development, manufacturing and selling of pharmaceutical products in the therapeutic areas of anti-virus, endocrine and metabolic diseases, cardiovascular diseases and others. The company is headquartered in Yichang, Hubei and currently employs 3,616 full-time employees. The company went IPO on 2015-12-29. The firm is also engaged in the research and development, marketing and distribution of pharmaceuticals. The products of the Company include anti-viral drugs, endocrine and metabolic drugs and cardiovascular drugs. Its main products include Kewei, Ertongshu, Oumeining, Xinhaining and Xining.
Contact
IPO
Employees
Officers
The intrinsic value of one YiChang HEC ChangJiang Pharmaceutical Co Ltd stock under the Base Case scenario is 22.64 HKD.
Compared to the current market price of 12.5 HKD, YiChang HEC ChangJiang Pharmaceutical Co Ltd is Undervalued by 45%.
You don't have any saved screeners yet
